Jeremy Clarkson now in remission from prostate cancer: what PSA testing actually shows men over 50

Jeremy Clarkson has told viewers of Clarkson's Farm that he was diagnosed with what he described as an aggressive prostate cancer, underwent surgery and is now in remission. The 65-year-old presenter said on the show — and in subsequent comments to the BBC — that early detection was the reason his outcome was favourable.

Clarkson said the diagnosis began with a routine blood test that showed a raised prostate-specific antigen, or PSA, level. PSA is a protein made by the prostate gland that leaks into the bloodstream; levels rise with age, with prostate enlargement and with cancer. An elevated PSA does not on its own confirm cancer, but it is the trigger for further investigation.

Clarkson's disclosure has reopened the public-health argument around the UK's most common cancer in men — roughly 55,000 new diagnoses a year. The NHS does not run a national prostate-screening programme for asymptomatic men. The reasoning: the PSA test produces a high rate of false positives, and some slow-growing tumours may never affect a man's life expectancy.

NHS guidance does allow any man over 50 to request a PSA test from his GP. This is framed as an "informed choice": the patient is expected to discuss benefits and risks with the doctor before the test goes ahead. Risk is higher for Black men, for men with a first-degree relative who had prostate cancer and for those with known genetic predispositions such as BRCA mutations.

Prostate Cancer UK said calls to its helpline and uses of its online risk-checker tool quadrupled in the hours after Clarkson's broadcast. "A single recognised name's diagnosis story will often trigger more requests than weeks of public-awareness campaigning," the charity said in a statement.

Clinically, PSA testing sits alongside imaging and biopsy. Multi-parametric MRI has, over the past decade, substantially reduced unnecessary biopsies: it now allows doctors to sample only suspicious areas rather than systematically biopsying the whole gland. That sequencing change — PSA, then MRI, then targeted biopsy — is now standard NHS practice.

Clarkson did not share details of the surgery type or recurrence rate, but for prostate cancers caught early — confined to the gland — five-year survival sits above 95 per cent. For more advanced disease, the standard of care is a combination of radiotherapy and hormone therapy, and outcomes drop sharply once the disease has spread to the bones.

Clinicians caution against treating Clarkson's case as proof that everyone should be tested. Vincent Gnanapragasam, an oncological surgeon at the University of Cambridge, said in NHS-approved guidance: "Mass PSA screening can lead to overtreatment of slow-growing cancers; the side effects, including incontinence and sexual dysfunction, are not trivial."

Against that, the 15-year follow-up data from the ProtecT trial, published in 2024, showed that treating early-stage prostate cancer does reduce long-term mortality compared with active monitoring — though the data still pre-dates routine MRI staging. For higher-risk profiles, surgery or radiotherapy is preferred to monitoring.

Clarkson's message is simple: "If you're over 50, go and see your doctor. Asking is free." That call lines up with the informed-choice model clinicians have advocated for years — a decision made on individual risk, age and health history, rather than blanket screening or total avoidance.